Study | Kundapur et al. [8] | Gondi et al. [9] | Ghia et al. [10] | Marsh et al. [11] | Wan et al. [12] | Harth et al. [13] |
---|---|---|---|---|---|---|
No of metastatic lesions | NA | 1131 | 272 | 697 | 2270 | 856 |
No of pts | NA | 371 | 100 | 107 | 488 | 100 |
No of metastases in HA region (%) | NA | 34 (3.0%) | 9 (3.3%) | 16 (2.3%) | 7 (0.3%) | 11 (1.3%) |
No of pts. with metastases in HA region (%) | NA | 22 (8.6%) | 8 (8.0%) | 16 (15.0%) | 7 (1.4%) | 11 (11.0%) |
No of metastatic lesions for SCLC pts | 359 | NA | 24 | 145 | 225 | 201 |
No of SCLC pts | 59 | 38 | 10 | 11 | 44 | 11 |
No of metastases in HA region for SCLC pts. (%) | 3 (0.8%) | NA | 3 (12.5%) | 3 (2.1%) | 1 (0.4%) | 5 (2.5%) |
No of SCLC pts. with metastases in HA region (%) | 3 (5.1%) | 4 (10.5%) | 3 (30.0%) | 3 (27.3%) | 1 (2.3%) | 5 (45.5%) |